PatentApr 28, 2026, 08:08 AM
ALLR Stenoparib DRP® Test Patent Allowance from USPTO
AI Summary
Allarity Therapeutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the DRP® companion diagnostic specific to stenoparib. This patent is expected to be formally granted within three months and would provide exclusivity at least into 2039 for stenoparib when used in concert with the DRP® test. This is a significant step in the company's global strategy to expand and protect the commercial potential of stenoparib, especially as it seeks to accelerate approval for Ovarian and other cancers.
Key Highlights
- USPTO issued Notice of Allowance for Allarity's DRP® companion diagnostic patent for stenoparib.
- Patent expected to be formally granted within three months, subject to administrative procedures.
- Patent would provide exclusivity at least into 2039 for stenoparib when used with the DRP® test.
- Allowed claims cover methods for predicting clinical benefit and selecting patients based on gene expression profiles.
- Allarity previously secured European and Australian patents for Stenoparib DRP® and holds 18 other DRP® patents.
- Patent applications for Stenoparib DRP® remain pending in Canada, Japan, China, and India.
Price Impact
More from ALLR